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1. Introduction
The human stomach is an unfriendly place for most infective bacteria probably due to the very 
low pH found in this place. However, the first isolation of a spiral-shaped, Gram-negative 
and microaerophilic bacterium in 1982 by Warren and Marshall [1] significantly changed the 
concepts of gastric microbiology.
Initially, this bacterium was named Campylobacter pyloridis, but analysis of nucleic acid 
sequence and ultrastructural studies besides the helical shape allowed differentiation of this 
genus to Helicobacter. Finally, the species was named pylori because it can be found most often 
in the antral mucosa, near the pylorus [2].
Helicobacter pylori (H. pylori) organisms are 2.5–5.0 μm long and 0.5–1.0 μm wide, with two 
to six unipolar-sheathed flagella, which are essential for bacterial motility [3]. It has been 
described that bacteria can exist in three different morphologic forms: the viable and cultur-
able spiral form, the viable but nonculturable (VBNC) coccoid form which are less virulent, 
and the nonviable degenerative H. pylori form [4].
Colonization with H. pylori is commonly acquired during childhood and induces chronic 
gastritis in all infected individuals unless specific treatment is given [5, 6]. While over 80% 
of infected subjects remain asymptomatic [7], H. pylori chronic infection has been associated 
with the development of various clinical disorders of the upper gastrointestinal tract, such 
as chronic gastritis, peptic ulcer disease, mucosa-associated lymphoid tissue (MALT) lym-
phoma, and gastric adenocarcinoma [8]. In fact, H. pylori infection is a significant risk factor 
for the development of gastric cancer, and bacterium is classified as a group I carcinogen by 
the World Health Organization [9].
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Although H. pylori is primarily responsible for the upper gastrointestinal diseases, only 10% 
of people colonized with this bacterium portray disease symptoms. It suggests that host and 
bacterial factors also contributed to differences in H. pylori pathogenicity [10, 11]. For instance, 
the risk of developing gastric cancer is also related to genetic characteristics of the host and 
environmental factors, which, associated with specific bacterial strain characteristics, influ-
ence the severity of the chronic inflammatory response [12, 13].
H. pylori is perhaps the most ubiquitous and successful human pathogen, since it colonizes 
the stomach of more than 50% of the world population [14, 15]. It has been demonstrated 
that H. pylori has a long period of coevolution with humans, going back at least since human 
migration out of Africa about 60,000 years ago [16, 17]. There are very well-characterized 
mechanisms of adaptation which was developed by ancestral H. pylori over the time. Through 
selection and coevolution, this bacterium established measures which actively and passively 
avoid the human immune response [18].
H. pylori infection results in recruitment of neutrophils, lymphocytes, and macrophages into 
the gastric mucosa through the induction of several cytokines such as TNF-α, IL-6, and IL-8 
[19, 20]. It is believed that the immune response during infection plays an important role in 
the pathogenesis. H. pylori successfully establishes a chronic infection by achieving a delicate 
balance between inducing immune response and surviving in the inflammatory milieu by 
using an array of important virulence factors [15].
H. pylori presents important virulence factors which are essential both for bacterium coloniza-
tion and maintenance in the human stomach (such as urease and flagella) and for the inter-
action with the gastric epithelial cells, the bacterial adhesins (blood group antigen-binding 
adhesion (BabA), sialic acid-binding adhesion (SabA), AlpA and AlpB, HopZ, and OipA). 
Besides, virulence factors involved in gastric inflammation are important for the develop-
ment of chronic infection and clinical symptoms of gastrointestinal diseases (the principal are 
cytotoxin-associated gene-pathogenicity island (cagPAI), vacuolating cytotoxin A (VacA), and 
duodenal ulcer promoting gene (dupA)).
2. Epidemiology of H. pylori infection
The H. pylori infection has emerged as one of the most common chronic bacterial infections 
worldwide and affects more than half of the world’s population, with clinical signs of infec-
tion only manifesting in <20% of these individuals [21].
H. pylori is thought to be indigenous to the human population and is well adapted to existing 
in the human stomach for the lifetime of its host [22] unless eradication using appropriate 
chemotherapeutic agents is successful. Lifelong colonization seems to be due to the ability 
of some strains of H. pylori to both adapt to the host’s immunological responses and to also 
withstand the constantly changing gastric environment [23].
The rate of H. pylori infection differs among groups as well as within the population. Strains 
from different geographical areas exhibit phylogeographic features [24–26]. The genomic 
Helicobacter Pylori - New Approaches of an Old Human Microorganism4
patters of H. pylori have been shown to be extremely diverse, and gastric mucosa may be 
colonized by strains with small differences in the genomic patterns suggesting subtype varia-
tion [27].
The prevalence of H. pylori infection varies widely by geographic area, age, race, and 
socioeconomic status. While the infection is on a fast decline in the most of the Western 
countries, mainly due to the success of therapeutic regimens and improved personal and 
community hygiene that prevents reinfection, in developing countries, the prevalence rates 
can reach 90% and is higher among individuals belonging to low socioeconomic status 
group [28, 29]. It occurs especially due to failure of treatment and emergence of drug resis-
tance [25, 30].
Most studies suggest that males and females are infected at approximately the same rates 
[31–33]. In spite of it, a meta-analysis population-based study reported a male predominance 
of H. pylori-related diseases in adults but not in children [34].
The infection probably occurs in the childhood, and children are often infected by a strain 
with a genetic fingerprint identical to that of their parents [35]. Besides, local prevalence of 
H. pylori within a country also should be considered, and there are estimates that infection is 
more common in rural developing areas than in urban developed ones [36].
Moreover, differences by ethnic and racial groups are evident [31, 32, 37]. In addition, the 
main risk factors of H. pylori infection, especially if present during childhood, have been 
associated with socioeconomic status. Malaty and Graham [38] demonstrated that there is 
probably an inverse correlation between prevalence and socioeconomic status. It has also 
been reported that overcrowding, such as living in a crowded environment, sibship size, 
number of persons or children in the home, number of persons per room, crowding index, 
and living in an institutionalized population, is a situation consistently related to H. pylori 
positivity [39–42].
Finally, it is important to consider that the pathogenetic role of H. pylori in gastroduodenal 
pathologies has been elucidated and confirmed in the past 30 years [43] redirecting the scien-
tific and medical understanding of great part of gastrointestinal diseases. The development 
of effective therapies against H. pylori infection has progressed, and its successful eradication 
leads to healing of chronic active gastritis and reverses inflammation of the mucosa. In spite of 
it, the challenge nowadays is gastric cancer and the understanding of gastric carcinogenesis, 
almost always associated with H. pylori long-term infection [44].
3. Transmission pathways
Although the natural niche for H. pylori is the human stomach, some questions about other 
possible reservoirs for bacterium have been appearing in the last years. Nevertheless, most 
part of the questions about the transmission of H. pylori remains unclear, and, because of it, 
the possible modes of transmission are still unknown. Consequently, the routes of transmis-
sion of H. pylori are supposed to occur via an array of different pathways.
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Some important studies have reported and highlighted the importance of H. pylori biofilms, 
the presence of coccoid forms within the biofilm, and resistance, providing insight into the 
prevalence of coccoid forms in the gastric mucosa. These reports are very important because 
these can bring a better understanding about the mechanisms behind recalcitrant coccoid 
states and how they can phenotypically shift into more virulent spiral forms [21, 45–47].
The infection is typically acquired in early childhood and once established commonly persists 
throughout life unless treated. Person-to-person transmission within the family appears to 
be the predominant mode of transmission, particularly from mothers to children and among 
siblings, indicating that intimate contact is important [29, 48–50]. The route of transmission is 
uncertain, but the gastro-oral, oral-oral, and fecal-oral routes are likely possibilities.
The community and environment may play additional roles for H. pylori transmission in some 
settings. Molecular analyses show that the microorganism is also present in various aquatic 
environments suggesting that human-fecal-contaminated water sources could be a plausible 
reservoir of the pathogen. The persistence of the environment virulent H. pylori strain in a 
clustered state, such as the biofilm, suggests a long-term survival of the bacterial commu-
nity outside the host, enabling bacterial transmission with important clinical repercussions 
[21, 46]. In addition, zoonotic transmission by houseflies [51–53] and some domestic animals 
such as dogs, cats, and sheep [54–56], as well as iatrogenic transmission [57, 58], have been 
proposed. Besides, there can be factors both from host and bacterium which may modify the 
acquisition and persistence of H. pylori infection.
Another possibility of H. pylori transmission which has been extensively reported is the water. 
The contamination of drinking water by human feces has been suggested as one of the possible 
routes of H. pylori transmission, and it has been demonstrated that the microorganism is present 
in the so-called viable but nonculturable state in this unsuitable environment, meaning that their 
role in fecal-oral transmission via contaminated water sources cannot be disregarded [47, 59]. 
The first evidences of water transmission route were obtained in studies developed in some Latin 
American countries—Peru, Colombia, Chile, and Venezuela—and since then H. pylori has been 
detected in several water sources, including lakes, rivers, tap water, well water, irrigation water, 
and sea water, and also in water distribution systems. Consequently, it can be hypothesized that 
drinking water could be the pathway for returning to humans [14]. Consequently, it can be sug-
gested that water can serve as an intermediate source in the fecal-oral transmission of H. pylori, 
acting as a reservoir in which this pathogen can survive for long periods.
4. H. pylori eradication therapies
The principal cases in which H. pylori have to be eradicated have been discussed in several 
guidelines worldwide, also considering that this microorganism is sensitive to only a few 
medications, and their widespread use in other kind of infections has led to a reduction in 
their effectiveness against the bacterium.
The infection is typically treated with combinations of two to three antibiotics along with a 
proton pump inhibitor (PPI), taken concomitantly or sequentially for periods ranging from 3 
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to 14 days. In spite of it, there is no treatment regimen which guarantees cure of H. pylori infec-
tion in 100% of patients. Individuals should be asked about any previous antibiotic uses, infor-
mation that has to be taken into consideration when choosing an H. pylori treatment regimen.
Clarithromycin triple therapy consisting of a PPI, clarithromycin, and amoxicillin or metronida-
zole for 14 days remains a recommended treatment option in regions where H. pylori clarithromy-
cin resistance is known to be <15% and in patients with no previous history of macrolide exposure 
for any reason. Bismuth quadruple therapy consisting of a PPI, bismuth, tetracycline, and a 
nitroimidazole for 10–14 days is a recommended first-line treatment option. Concomitant therapy 
consisting of a PPI, clarithromycin, amoxicillin, and nitroimidazole for 10–14 days is a recom-
mended first-line treatment option. Levofloxacin triple therapy consisting of a PPI, levofloxacin, 
and amoxicillin for 10–14 days is a suggested first-line treatment option. Finally, fluoroquinolone 
sequential therapy consisting of a PPI and amoxicillin for 5–7 days followed by a PPI, fluoroqui-
nolone, and nitroimidazole for 5–7 days is a suggested first-line treatment option [60–62].
This book comprehends important chapters that will certainly clarify the understanding of 
this microorganism infection, which affects half of the world population, despite promoting 
clinical symptoms and disease in only a small part of the infected individuals.
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